TLC C 53

Drug Profile

TLC C 53

Alternative Names: LIP-PGE1; Ventus

Latest Information Update: 02 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Liposome Company
  • Developer Taisho Pharmaceutical; The Liposome Company
  • Class Prostaglandins
  • Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery restenosis; Cystic fibrosis; Inflammation; Myocardial infarction; Peripheral vascular disorders; Septic shock; Systemic inflammatory response syndrome; Thrombosis
  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 31 May 2000 The Liposome Company has been acquired by Elan Corporation
  • 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in European Union (Unknown route)
  • 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top